PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 12: Articles 5501-6000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Contraceptive sterilization: trends, options, and surprising new data.
  2. Contraceptive switching in Bangladesh.
  3. Contraceptive switching patterns in rural Bangladesh.
  4. Contraceptive technologies: how much choice do we really have?
  5. Contraceptive technology update and quality client care services. A guide for pharmacists. Zimbabwe.
  6. Contraceptive usage and reasons for method-switching and discontinuation [letter]
  7. Contraceptive use among women attending college: results from a pilot study.
  8. Contraceptive use and knowledge about health. [Uso de anticonceptivos y conocimientos sobre salud.]
  9. Contraceptive use and maternal-child health care utilization: does service availability matter?
  10. Contraceptive use and sexual activity among teenage mothers receiving AFDC.
  11. Contraceptive use dynamics in Zimbabwe: postpartum contraceptive behaviour.
  12. Contraceptive use in women with bacterial vaginosis.
  13. Contraceptive use triples in Uganda.
  14. Contraceptives and HIV transmission [letter]
  15. Contraceptives and HIV transmission. Marx replies [letter]
  16. Contraceptives at your doorstep: two urban and two rural areas of Bangladesh.
  17. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the Copper T 380A IUD.
  18. Contraceptives.
  19. Correlates of contraceptive failure among clients attending an antenatal clinic in Nairobi.
  20. A cost analysis of family planning in Bangladesh.
  21. Cost-effectiveness of family planning and maternal and child health alternative service-delivery strategies in rural Bangladesh.
  22. Costs and benefits of Vietnam's national investment in population and family planning from 1979 to 2010. Final report.
  23. Costs of family planning programmes in fourteen developing countries by method of service delivery.
  24. Counseling men vs. women: family planning in Kenya. Draft.
  25. Counseling the husbands of postabortion patients in Egypt: effects on husband involvement, patient recovery and contraceptive use. Final report.
  26. A cross-sectional evaluation of the DISH family planning mass media campaign. Interviews with new family planning clients.
  27. Cultural factors constraining the introduction of family planning among the Kassena-Nankana of northern Ghana.
  28. Current issues in contraception.
  29. Current practice of family planning in China.
  30. Current status of injectable hormonal contraception, with special reference to the monthly method.
  31. Cyclic and individualized administration of gonadotropin-releasing hormone agonists plus progestogens: an alternative protocol for contraception.
  32. Data complement anti-STD activity of PRO 2000 gel. Contraceptives.
  33. Data sheet charts family planning progress.
  34. Deciding on a method of natural family planning.
  35. Declaration on the Rights of Research, Development and Use of Contraceptives. [Declaracion sobre los Derechos de Investigacion, Desarrollo y Uso de Anticonceptivos.]
  36. The decline of fertility in Malta: the role of family planning.
  37. Defining quality in family planning services.
  38. Defining quality of care and adherence to reproductive rights in family planning programmes.
  39. Deliberate birth control under a high-fertility regime: reproductive behavior in China before 1970.
  40. The delivery of maternal, child health and family planning services through cluster visitation.
  41. Demand for family planning services in rural Bangladesh: effect of cash prices and access.
  42. Denial of contraceptive use among known contraceptive adopters in a rural area of northern Ghana.
  43. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
  44. Despite good intentions, donor nations slow in support of family planning.
  45. Determinants for contraceptive use in young, single, Danish women from the general population.
  46. Determinants of contraceptive failure, switching, and discontinuation: an analysis of DHS contraceptive histories.
  47. Determinants of contraceptive use among the young and newly-wed couples.
  48. Determinants of contraceptive use among women of reproductive age in Great Britain and Germany. I: Demographic factors.
  49. Determinants of contraceptive use among women of reproductive age in Great Britain and Germany. II: Psychological factors.
  50. Determinants of contraceptive use: from birth control to fertility awareness [editorial]
  51. Determinants of induced abortion: the role of perceived and experienced contraceptive side effects and lack of counseling.
  52. Determinants of maternal and child immunisation and family planning acceptance: an inter-state analysis.
  53. Development of male contraceptive vaccine -- a perspective.
  54. Development of materials on breastfeeding appropriate for family planning audiences (and vice versa)
  55. Differences between adolescent girls seen at their first visits to a family planning center during two different time periods. [Diferencias existentes entre las adolescentes atendidas en primera visita en un centro de planificacion familiar en dos periodos de tiempo.]
  56. Differential acceptance of family planning methods in India: a quantitative analysis.
  57. Directive No. 37-TTg of January 17, 1997, of the Prime Minister on accelerating the implementation of the Strategy on Population and Family Planning to the Year 2000.
  58. Do different brands of oral contraceptives differ in their effects on cardiovascular disease?
  59. Do integrated MCH / family planning programs increase contraceptive use? Findings from two North African studies.
  60. Does abstinence make the heart grow fonder? Two writers share what happened when they practiced natural family planning.
  61. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1 / BRCA2 mutations more than in other women?
  62. Does the menstrual cycle and use of oral contraceptives influence the risk of low back pain? A prospective study among female soccer players.
  63. Donor fatigue hits family planning in developing world.
  64. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system.
  65. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
  66. Economics of the contraception of adolescents. [Economicitatea contraceptiei la adolescenti.]
  67. Ectopic pregnancies in women using intrauterine contraceptive devices (IUDs) [Ektopicne trudnoce kod korisnica intrauterinih kontraceptivnih ulozaka.]
  68. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
  69. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
  70. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
  71. The effect of hormonal contraception on liver function. [Vliv uzivani hormonalni kontracepce na jaterni funkce.]
  72. The effect of oral contraceptive agents on the basal metabolic rate of young women.
  73. Effect of oral contraceptives on haemostasis variables.
  74. Effect of provider characteristics on choice of contraceptive provider: a two-equation full-information maximum-likelihood estimation.
  75. The effect of risk-assessment based counseling on contraceptive behavior [abstract]
  76. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
  77. Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive.
  78. Effective family planning service delivery: testing of a new approach.
  79. The effectiveness of family planning programs evaluated with true experimental designs.
  80. The effectiveness of natural family planning methods for birth spacing: a comprehensive review.
  81. Effects of age and non-hormonal contraception on menstrual cycle characteristics.
  82. Effects of couples' characteristics on contraceptive use in sub-Saharan Africa: the Ghanaian example.
  83. The effects of family planning programmes on fertility preferences: evidence from Bangladesh.
  84. Effects of husband involvement on postabortion patients' recovery and use of contraception in Egypt.
  85. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness.
  86. The effects of pregnancy experience on contraceptive practice.
  87. Effects of timing of conception on birth weight and preterm delivery of natural family planning users.
  88. Effects of two combined monophasic and triphasic ethinylestradiol / gestodene oral contraceptives on natural inhibitors and other hemostatic variables.
  89. Egypt In-Depth Study on Reasons for the Nonuse of Family Planning. Preliminary report.
  90. Egyptian experience in family planning promotion: IEC capacity-building and institutionalization.
  91. EMEA and third-generation oral contraceptives [letter]
  92. Emergency contraception [letter]
  93. Emergency contraception -- expanding opportunities for primary prevention.
  94. Emergency contraception as a backup method.
  95. Emergency contraception to the rescue. How women can reduce the risk of pregnancy after unprotected sex.
  96. Emergency contraception with levonorgestrel, alternative to the Yuzpe regimen. [Contraceptia de urgenta cu Levonorgestrel, alternativa a regimului YUZPE.]
  97. Emergency contraception. Fact sheet.
  98. Emergency contraception. The pill's little-known secret goes public.
  99. Emergency contraception: a new training pack for primary health care teams.
  100. Emergency contraception: a resource manual for providers.
  101. Emergency contraception: a second chance at preventing adolescent unintended pregnancy.
  102. Emergency contraception: all talk, no action? Q and A.
  103. Emergency contraception: is the secret getting out? Kaiser Family Foundation 1997 National Surveys of Americans and Health Care Providers on Emergency Contraception. Executive summary.
  104. Emergency contraception: is the secret getting out? Kaiser Family Foundation National Surveys of Americans and Health Care Providers on Emergency Contraception. Toplines.
  105. Emergency contraception: preventing unintended pregnancy.
  106. Emergency contraception: the nurse's role in providing postcoital options.
  107. Emergency contraception: what teens need to know.
  108. Emergency contraceptive methods revisited [editorial]
  109. Emergency postcoital contraception.
  110. Emergency postcoital contraception.
  111. Emergency postcoital contraception.
  112. Employer-based family planning projects. A summary.
  113. The endometrial approach in contraception.
  114. Endometrial interference of synthetic estrogens in fertility regulation. Is it necessary to interfere with the antiovulatory mechanism at the central nervous system level in order to obtain contraception? [Interferencia endometrial de los estrogenos sinteticos en la regulacion de la fertilidad. Es necesario el mecanismo antiovulatorio a nivel del sistema nervioso central, para obtener la anticoncepcion?]
  115. The equity and efficiency of doorstep delivery of contraceptives in Bangladesh.
  116. Estimates and explanations of gender differentials in contraceptive prevalence rates.
  117. Estimation and analysis of sampling errors for the 1992 National Fertility and Family Planning Survey.
  118. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
  119. Ethical and health implications of directive counseling on long-acting contraception [letter]
  120. Evaluating the effectiveness of workshop interventions on contraceptive use among first-year college students.
  121. An evaluation of initiatives to improve family planning use by African-American adolescents.
  122. An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9.
  123. Eve's herbs. A history of contraception and abortion in the West.
  124. Everyone should have access to contraception. [Alle bor ha tilgang til prevensjon.]
  125. Examining the increasing popularity of traditional contraceptive methods in Honduras. [Examen del aumento en la popularidad de los métodos anticonceptivos tradicionales en Honduras.]
  126. Exit questionnaire for family planning clients attending the service delivery point. Checklist 3.
  127. Expanding the availability and improving delivery of natural family planning services and fertility awareness education: providers' perspectives.
  128. Experience with family planning and perceptions about voluntary sterilization among women seeking reproductive health services at four Romanian hospitals (ROM-02-SV-1-P)
  129. Experiences of new contraceptive users in Bamako, Mali: an exploratory study of reproductive decision making. Preliminary results.
  130. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.
  131. Factors affecting contraceptive use in Ghana.
  132. Factors associated with traditional birth attendant provision of family planning services.
  133. Factors influencing the reliability of oral contraceptives.
  134. Factors to address when periodic abstinence is offered by multi-method family planning programs.
  135. Facts about emergency contraception.
  136. Facts about today's low-dose oral contraceptives. Patient update.
  137. Family planning -- what needs to be taught? [letter]
  138. Family planning -- what needs to be taught? A view from general practice in the West Midlands, UK.
  139. Family planning and AIDS awareness in religious and tribal groups in Tanzania: gender differences.
  140. Family planning and health insurance. A summary.
  141. Family planning and the real world.
  142. Family planning and women's empowerment: challenges for the Indonesian family. Final report.
  143. The family planning aspects of the practice of traditional healers in Ibadan, Nigeria.
  144. The Family Planning Association of Pakistan's Faisalabad program for men: a case study.
  145. Family planning becomes widespread. [La regulation des naissances se generalise.]
  146. Family planning choice behaviour in urban slums of Bangladesh: an econometric approach.
  147. Family planning clinics through women's eyes and voices: a case study from rural Bangladesh.
  148. Family planning counselling -- a priority for post abortion care.
  149. Family planning experiences of Vietnamese women.
  150. Family planning handbook for health professionals. The sexual and reproductive health approach.
  151. Family planning in Croatia.
  152. Family planning in Isparta, Turkey.
  153. Family planning in Lhasa.
  154. Family planning in Pakistan: have we reached a turning point?
  155. Family planning in poverty-ridden Nicaragua.
  156. Family planning in reproductive health: policy framework, strategies and guidelines.
  157. Family planning in Russia.
  158. Family planning in the 21st century: perspective of the International Planned Parenthood Federation.
  159. Family planning in Tibet.
  160. Family planning information sources and media exposure among Nigerian male adolescents: a case study of Ekiti southwest local government area of Ondo State.
  161. Family planning is reducing abortions.
  162. Family planning knowledge, attitudes and practices among currently married men and women in Jordan. Final report.
  163. Family planning knowledge, attitudes and practices in Jordan. Final report. Information, Education and Communication Project.
  164. Family Planning Management Development, 1995-2000.
  165. Family planning management for the migrant population in sending areas. Urban family planning programme.
  166. Family planning management in state-owned enterprises: the case of No. 1 Automobile Group Corporation. Urban family planning programme.
  167. Family planning needed after abortion.
  168. Family planning needs and STD risk behaviours of female psychiatric out-patients.
  169. Family planning nurses and prescribing in the UK: a survey of attitudes and experiences.
  170. Family planning outcomes of male chronically ill psychiatric outpatients.
  171. Family planning practices among Muslims in selected districts of Uttar Pradesh.
  172. Family planning programme in seven most populous developing countries -- a comparison.
  173. Family planning reaches Mongolia's spacious steppes.
  174. Family planning requirements of adults with congenital heart disease [editorial]
  175. Family planning saves lives, prevents abortion.
  176. Family planning saves lives. 3rd ed.
  177. Family planning services in developing countries: an opportunity to treat asymptomatic and unrecognised genital tract infections?
  178. Family planning services in Nairobi. Report of a workshop for strengthening the utilization of findings from research studies of clinic and community based family planning services of the Nairobi City Council.
  179. Family planning training in the undergraduate curriculum: a national survey and its implications.
  180. Family planning unmet need in Bangladesh: shaping of a client-oriented strategy.
  181. Family planning week in Ukraine.
  182. Family planning, family welfare and women's activities in Indonesia. Final report.
  183. Family planning.
  184. Family planning. [Planification familiale.]
  185. Family planning. [Planification familiale.]
  186. Family planning: the way to Malawi's future. Using training to achieve quality.
  187. Family-building and family planning evaluation.
  188. Farmers knew prosperity lies in family planning: Prof. Gao Yuanxiang.
  189. FDA opens door for emergency contraception.
  190. FDA seeks new-drug applications for "morning-after" contraception.
  191. Fearing side effects, many Turkish women choose traditional contraceptives.
  192. The female condom: expanding contraceptive options.
  193. Fertility and contraception in Europe: the case of low fertility in Southern Europe.
  194. Fertility in Tanzania: do contraception and sub-fertility matter?
  195. Fertility preferences and contraceptive practice in Nigeria.
  196. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices.
  197. Fertility remains high in Guatemala despite increasing use of contraception.
  198. Fertility transition in Zimbabwe: determinants of contraceptive use and method choice.
  199. Fertility, contraceptive prevalence, and maternal-child health: El Salvador 1988-1993. [Fecundidad, prevalencia anticonceptiva y salud materno infantil. El Salvador 1988-1993.]
  200. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth.
  201. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth.
  202. FHI study examines N-9 film effect on STDs. Contraceptive update.
  203. Fighting for child health: race, birth control, and the state in the Jim Crow South.
  204. Final report of activities for "Improved Reproductive Health and STD Services for Women Presenting to Family Planning Services in North Jakarta".
  205. Final report. Emergency Contraception as an Element in the Care of Rape Victims. June 1, 1996 - June 15, 1997.
  206. Final report. Training for Jiggasha replication. Cost reimbursable contract between JHU and Family Planning Services and Training Center (FPSTC), July 2, 1993 -September 30, 1994, AS-BAN-11, Bangladesh.
  207. Final report. Trial period for developing a proposal to strengthen family planning services in the Hospital Escuela, November 1996 - February 1997. [Informe final. Periodo de prueba para desarrollar una propuesta para fortalecer servicios de planificacion familiar en el Hospital Escuela. Noviembre, 1996 a Febrero, 1997.]
  208. Final report: Nepal Family Planning Communication Survey. Fixed Price Contract between the Johns Hopkins University / Population Communication Services / Population Information Program and Valley Research Group (VaRG), September 22, 1994 -April 30, 1996, AS-NEP-08.
  209. Foes fail to reinstate US family-planning cash ban.
  210. Foreign assistance: impact of funding restrictions on USAID's voluntary family planning program. Report to Congressional requesters.
  211. The frequency and spectrum of congenital anomalies in natural family planning users in South America: no increase in a case-control study.
  212. From family planning to reproductive health and beyond. Draft. [De la planificacion familiar a la salud reproductiva y mas alla. Borrador para libro.]
  213. From population control politics to chemicals: the WHO as an intermediary organization in contraceptive development.
  214. From the Maya to family planning: the demography of the isthmus. [De los Mayas a la planificacion familiar: demografia del Istmo.]
  215. Funding for international family planning attacked.
  216. Funding of contraceptive implants is crucial [letter]
  217. The future of male contraception: immunocontraception by prevention of gamete interaction. [Le futur de la contraception masculine: immunocontraception par la prevention de l'interaction gametique.]
  218. Future of natural family planning and reproductive health awareness. What are the implications of the findings and discussion of this conference for future directions in NFP and reproductive health awareness?
  219. Gender, sexuality and communication issues that constitute barriers to the use of natural family planning and other fertility awareness-based methods.
  220. Geographic information systems, spatial network analysis, and contraceptive choice.
  221. Gestagens, danazol and antiprogestogen in emergency contraception.
  222. A glance at keys to success for commercial sector involvement in family planning in developing countries.
  223. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
  224. Guide to the use of maternal-child health and family planning data. [Guide d'utilisation des donnees des programmes SMI / PF.]
  225. Guji, Guji, Angela] Family planning programme.

     

  226. Gynecology and family planning care for the woman infected with HIV.
  227. The GyneFix implant systems for interval, postabortal and postpartum contraception: a significant advance in long-term reversible contraception.
  228. GyneFix: intrauterine contraceptive implant. [GyneFix: implante contraceptivo intrauterino.]
  229. Haemostatic changes and the oral contraceptive pill.
  230. Haiti. Final report: "Continued Strengthening of Family Planning Supervision". Technical assistance to INHSAC.
  231. Health communication: lessons from family planning and reproductive health.
  232. Health status in contraceptive-using populations. [Condiciones de salud en poblaciones usuarias de anticonceptivos.]
  233. Helping the husband, maintaining harmony: family planning, women's work, and women's household autonomy in Indonesia. Final report.
  234. HIV and contraception.
  235. Hollywood with a heart. We should be seeking the maximum growth in family planning programs.
  236. Hong Kong reverts to Chinese rule but won't introduce China's strict birth-control policies.
  237. Hormonal contraception and breast cancer: convincing new conclusions.
  238. Hormonal contraception and cervical cancer.
  239. Hormonal contraception and ovarian pathology.
  240. Hormonal contraception and pelvic inflammatory disease.
  241. Hormonal contraception and thromboembolic disease. I. Epidemiological data. [Hormonalni antikoncepce a tromboembolicka nemoc. I. Epidemiologicka data.]
  242. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.
  243. Hormonal postcoital contraception.
  244. Hospital staff trained to provide family planning.
  245. House agrees with president that delay in international family planning aid causes harm.
  246. House battles over UN family planning funds.
  247. How do family planning workers' visits affect women's contraceptive behavior in Bangladesh?
  248. How does family planning save lives? Fact sheet.
  249. How family planning protects the health of women and children. Fact sheet.
  250. The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine.
  251. Immaculate contraception.
  252. The immediate effects of the pill safety scare on usage of combined oral contraceptives in north east England.
  253. Impact of "pill alert" on contraceptive use [letter]
  254. The impact of Congressional restrictions on international family planning and reproductive health programs: a case study.
  255. The impact of contraceptive methods on the onset of symptomatic vulvovaginal candidiasis within the menstrual cycle.
  256. Impact of family planning programme on fertility in Uttar Pradesh.
  257. The impact of the October 1995 "pill scare" on oral contraceptive use in the United Kingdom: analysis of a general practice automated database.
  258. Implantable contraception.
  259. Implantable hormonal and emergency contraception.
  260. Implementation of a demographic and contraceptive surveillance system in four counties in north China.
  261. The implementation of integrated mother and child health and family planning services.
  262. Implementing family planning programs in developing countries: lessons and reflections from four decades of Population Council experience.
  263. The importance of family planning in Ukraine.
  264. Improve family planning after pregnancy.
  265. Improving the Bangladesh Health and Family Planning Programme: lessons learned through operations research.
  266. Improving the urban family planning programme.
  267. Incidence and implications of altered semen quality on family planning.
  268. Incidence and outcome of pregnancies during contraceptive use. [Haufigkeit und Ausgang von Schwangerschaften unter Verhutung.]
  269. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives.
  270. Increasing access to contraception. Successful project in Bangladesh.
  271. Incrustation of contraceptive devices: ultrasound as a diagnostic tool [letter]
  272. Indonesia loses family planning advocate.
  273. The Indonesian population and family planning programs: an overview. Past, present, and future challenges.
  274. Inequality in sexual behavior and reproductive health outcomes: number of sexual partners and contraceptive use in Tanzania.
  275. Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics.
  276. The influence of quality of care upon contraceptive use in rural Bangladesh.
  277. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
  278. The influence of type of information, somatization, and locus of control on attitude, knowledge, and compliance with respect to the triphasic oral contraceptive Tri-Minulet.
  279. The influence of women's changing roles and status in Bangladesh's fertility transition: evidence from a study of credit programs and contraceptive use.
  280. Information dissemination and contraception acceptance in Costa Rica. [La difusion de informacion y la adopcion de anticoncepcion en Costa Rica.]
  281. Informed choice of contraception after an obstetric event, Subcontract No. CI96.69A. INOPAL III final technical report.
  282. Inhibition of follicular growth by two different oral contraceptives (monophasic and triphasic) containing ethinylestradiol and gestodene.
  283. Initial performance and impact of village based family planning workers in four districts in Punjab. Final report.
  284. Injectable contraceptives: underused and undervalued?
  285. Injectable contraceptives: what health workers need to know.
  286. An innovative approach to redefining unment need for family planning: results from a community-level study in Guatemala City.
  287. Innovative procedures in family planning.
  288. Integrating HIV prevention, STD, and family planning services. A sexual and reproductive health approach in Latin America and the Caribbean [letter]
  289. Integrating HIV prevention, STD, and family planning services. Comprehensive efforts in Philadelphia [letter]
  290. Integrating HIV prevention, STD, and family planning services. The availability of HIV services at different types of clinics: a survey [letter]
  291. Integrating HIV prevention, STD, and family planning services. The need for integrated government funding and services [letter]
  292. Integrating STI / HIV prevention into family planning services. Women's reproductive health.
  293. Integration of family planning with MCH in Shannan prefecture.
  294. An integration programme of poverty alleviation and development with family planning.
  295. International family planning funds will be expedited.
  296. Interval and postabortal contraception with the frameless GyneFix.
  297. Interview with the Grand Shaikh of al-Azhar Muhammad Sayyid al-Tantawi regarding family planning.
  298. Interviewer's manual. For use with model "A" questionnaire for high contraceptive prevalence countries. Demographic and Health Surveys Phase III.
  299. Interviewer's manual. For use with model "B" questionnaire for low contraceptive prevalence countries. Demographic and Health Surveys Phase III.
  300. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
  301. Intrauterine contraception. Effective practice and quality of care. A - Z of audit.
  302. The intrauterine contraceptive device: an acceptable alternative to sterilization in young women [letter]
  303. Intrauterine contraceptive devices act before fertilization [letter]
  304. Intrauterine contraceptive devices act before fertilization. Reply [letter]
  305. Intrauterine contraceptive devices and antigestagens as emergency contraception.
  306. Introducing sexuality within family planning: the experience of three HIV / STD prevention projects from Latin America and the Caribbean.
  307. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru.
  308. IPPF declaration on breast feeding, fertility and postpartum contraception. [Declaracao da IPPF sobre aleitamento materno, fertilidade e contracepcao pos-parto.]
  309. IPPF report, International Planned Parenthood Federation, December 1996. The pill and breast cancer: new information. [Informe de IPPF. Federacion Internacional de Planificacion de la Familia, Diciembre - 1996. La pildora y el cancer de mama: nueva informacion.]
  310. Is birth control counseling free of charge? (letter) [Er prevensjonsveiledning gratis?]
  311. Is development the best contraceptive? Evidences from Uttar Pradesh.
  312. Isolation and characterization of the primary structure of testis-specific L-type calcium channel: implications for contraception.
  313. Jiang Shuqin: a devoted family planning worker.
  314. Jordan family planning IEC needs assessment: findings and recommendations.
  315. Jordan national family planning communication strategy design workshop report, May 19-22, 1997.
  316. Jordan National Family Planning Communication Strategy. Design workshop report, May 19-22, 1997.
  317. In Kazakstan, contraceptive knowledge is nearly universal, but abortion rates remain high.
  318. Key developments in family planning.
  319. Knowledge and practice of contraception in Haiti: a factor in fertility decline over the last two decades? [La connaissance et la pratique de la contraception en Haiti: facteur de la baisse de la fecondite depuis deux decennies?]
  320. Knowledge and use of emergency contraception among women seeking termination of pregnancy in New South Wales [letter]
  321. Knowledge, attitude and practice of family planning in Mongolia.
  322. LAM as a natural method of family planning: future emphasis for the Institute for Reproductive Health.
  323. Latest Medicaid waivers break new ground for family planning.
  324. Latex allergy and contraception.
  325. Law of 30 August 1996 amending the law on family planning, protection of human fetuses, and the conditions under which pregnancy termination is permissible, and amending other laws.
  326. Lending a hand to midwives: the PROFIT revolving loan fund for midwives. Improving private family planning services in Indonesia.
  327. Lessons from FPMD. Decentralizing the management of health and family planning programs.
  328. Lessons from Narangwal about primary health care, family planning, and nutrition.
  329. The level of information and contraceptive methods used by students. [Nivelul de informatie si metode contraceptive utilizate de studente.]
  330. Levonorgestrel subdermal implants. Contraception on trial.
  331. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism?
  332. Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
  333. Little knowledge and limited practice: emergency contraceptive pills, the public, and the obstetrician-gynecologist.
  334. Local contraception in adolescents. [Contraceptia locala la adolescente.]
  335. Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C.
  336. A longitudinal study of birth control and pregnancy outcome among women in a Swedish population.
  337. Loss of radiopacity may impede localization of intrauterine contraceptive device.
  338. Low-dose oral contraceptives and 24-hour ambulatory blood pressure.
  339. Male contraception. [Antikonzeption beim Mann.]
  340. Male contraception: barrier methods still in the forefront. [Antikonzeption beim mann. Barrieremethoden nach wie vor im Vordergrund.]
  341. Male contraception: ideas for the future.
  342. Male involvement in family planning. Experiences from innovative projects. Final report.
  343. Male involvement in family planning: a case study spanning five generations of a South Indian family.
  344. Male involvement in family planning: a KABP study of Agra district, India. Final report.
  345. Mali: views of new contraceptive users.
  346. Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception.
  347. The marriage of mentally handicapped people and family planning services for them in Shanghai.
  348. Married women's ideal family size preferences and family planning practices: evidence from rural Kenya.
  349. The Marvelon issue and confidence in oral contraceptives (letter) [Marvelonsaken og tilliten til p-piller.]
  350. Maternal and child health services and adoption of family planning methods.
  351. Measures ensuring family planning coverage make progress, meet obstacles.
  352. Measuring contraceptive effectiveness: a conceptual framework [letter]
  353. Mechanism of action of intrauterine contraceptive devices [letter]
  354. Mechanism of action of intrauterine contraceptive devices. Reply [letter]
  355. Mechanism of intrauterine device contraceptive action [letter]
  356. Mechanism of intrauterine device contraceptive action. Reply [letter]
  357. Media exposure increases contraceptive use.
  358. Medicaid managed care and the family planning free-choice exemption: beyond the freedom to choose.
  359. Medical and service delivery guidelines for family planning. 2nd ed., 1997.
  360. Medical care cost savings from adolescent contraceptive use.
  361. Meeting of cooperating agencies involved with the Family Planning Management Development project, 13 February 1997, New York, New York.
  362. Men in Latin America: how they view family planning, sexual health, and reproductive health.
  363. Men's participation in family planning decisions in Kenya.
  364. Men's unmet need for family planning: implications for African fertility transitions.
  365. Menstrual bleeding changes with different contraceptive methods.
  366. The menstrual cycle and its relation to contraceptive methods: a reference for reproductive health trainers.
  367. Menstruation requirements: a significant barrier to contraceptive access in developing countries.
  368. Methods of contraceptive and sexual education in adolescents. [Metode de educatie contraceptiva si sexuala la adolescenti.]
  369. Migraine and oral contraceptives.
  370. Minimising risk in contraception.
  371. Minister Peng Peiyun stresses improved management and services. Urban family planning programme.
  372. The missing component in family planning in Tanzania.
  373. Mobilizing the resources of the for-profit sector for family planning. A summary.
  374. Model-based approaches to studying fertility and contraceptive efficacy.
  375. Modern combined oral contraceptives for pain associated with endometriosis.
  376. Modern oral contraceptives and cardiovascular disease.
  377. Modernization and family planning programs in Egypt.
  378. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women.
  379. Moral and policy issues in long-acting contraception.

     

  380. More about oral contraceptive sales in Norway. Response [letter]
  381. More health care providers prescribing emergency contraceptive pills, but many may be missing opportunities by not talking with patients about the option ahead of time. Many American women remain unaware or misinformed about widely-accepted medical practice of using birth control pills to prevent pregnancy after unprotected sex. News release.
  382. More teenagers seem to be seeking contraceptive advice from their general practitioner [letter]
  383. More than half of all Brazilian contraceptive users rely on sterilization.
  384. The more things change: contraceptive distribution in former Soviet countries.
  385. Morning-after birth control sanctioned by FDA head.
  386. Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives.
  387. Mother and child health and family planning in Yemen: how to approach it and the fallacies of implementation.
  388. Moving an NGO toward financial sustainability: the Family Planning Association of Kenya (FPAK)
  389. A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II.
  390. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin.
  391. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
  392. Multilevel analysis of health and family planning data [abstract]
  393. Myths about oral contraceptives.
  394. N-9 contraceptive film and the risk of STDs.
  395. National Conference on Urban Family Planning Programme.
  396. National Contraceptive Prevalence Survey 1996.
  397. The national family planning movement through charts and pictures, 1996/1997. [Gerakan keluarga berencana nasional dalam grafik dan gambar, 1996/1997.]
  398. National Family Planning Week, Ukraine, May 26 - June 1, 1997.
  399. Natural family planning effectiveness: evaluating published reports.
  400. Natural family planning in New Zealand: a study of continuation rates and characteristics of users.
  401. Natural family planning using the Billings method. [Naturlig fodselsregulering med Billingsmetoden.]
  402. Natural family planning with and without barrier method use in the fertile phase: efficacy in relation to sexual behavior: a German prospective long-term study.
  403. Natural family planning: suitability of the CUE method for defining the time of ovulation.
  404. Nepal family planning training strategy: an update. FCA-27.
  405. Neuroendocrine mechanism of anovulation in users of contraceptive subdermal implant of nomegestrol acetate (Uniplant)
  406. New contraceptive options for adolescents.
  407. New generation of oral contraceptives and their cardiovascular effects.
  408. New laws limit access to family planning in Colombia.
  409. A new national survey on men's role in preventing pregnancy: women and men think men need to be more involved in contraceptive choice and use. News release.
  410. No evidence to support intrauterine contraceptive device and embryo destruction [letter]
  411. Non-use of contraception among Chinese women.
  412. Observation of service delivery points (SDPs) and interview schedule for staff providing family planning at SDPs. Checklist 2.
  413. On the determination of contraceptive prevalence using health care utilization data.
  414. On the horizon: new options for contraception.
  415. Operationalising the concept of unmet need for family planning services: a case study.
  416. Operations research final technical report: Systematic Offering of Family Planning and Reproductive Health Services in Guatemala.
  417. Oral contraception and breast cancer risk. [Contraception orale et risque de cancer du sein.]
  418. Oral contraception and breast cancer. [Contraception orale et cancer du sein.]
  419. Oral contraception and cerebral thromboembolism.
  420. Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: findings in a large cohort study.
  421. Oral contraception and prevention: reproductive cancers.
  422. Oral contraception and smoking. Time trends for a risk behaviour in Finland.
  423. Oral contraception and venous thromboembolism. A New Zealand perspective.
  424. Oral contraceptive (OC) use and risk of breast cancer [letter]
  425. Oral contraceptive (OC) use and risk of breast cancer --reply [letter]
  426. Oral contraceptive compliance during adolescence.
  427. Oral contraceptive failure rates and oral antibiotics.
  428. Oral contraceptive knowledge and compliance in young women.
  429. An oral contraceptive perception scale for female adolescents.
  430. Oral contraceptive pills for heavy menstrual bleeding.
  431. Oral contraceptive pills. Prevention of ovarian cancer and other benefits.
  432. Oral contraceptive practice guidelines.
  433. Oral contraceptive use and protective behavior after missed pills.
  434. Oral contraceptives and back pain in women in a Swedish community.
  435. Oral contraceptives and bone metabolism.
  436. Oral contraceptives and breast cancer risk.
  437. Oral contraceptives and endometriosis.
  438. Oral contraceptives and liver cancer.
  439. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). The Collaborative MILTS Project Team.
  440. Oral contraceptives and myocardial infarction.
  441. Oral contraceptives and myocardial infarction: new evidence leaves unanswered questions.
  442. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study.
  443. Oral contraceptives and systemic lupus erythematosus.
  444. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
  445. Oral contraceptives and venous thromboembolism [letter]
  446. Oral contraceptives and venous thromboembolism [letter]
  447. Oral contraceptives and venous thromboembolism [letter]
  448. Oral contraceptives and venous thromboembolism [letter]
  449. Oral contraceptives and venous thromboembolism [letter]
  450. Oral contraceptives and venous thromboembolism [letter]
  451. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias.
  452. Oral contraceptives and venous thromboembolism: acquired APC resistance? [letter]
  453. Oral contraceptives and venous thromboembolism: acquired APC resistance? [Reply] [letter]
  454. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives.
  455. Oral contraceptives are drug of choice for menorrhagia in the Netherlands [letter]
  456. Oral contraceptives hold top position as leading choice for women.
  457. Oral contraceptives not a risk factor for cardiovascular disease.
  458. Oral contraceptives, estrogen replacement therapy and venous thromboembolism. [Estrogenotherapie et maladie thromboembolique veineuse.]
  459. Oral contraceptives, reproductive factors and p53 gene expression in colorectal cancer.
  460. Oral contraceptives: cardiovascular risks and clinical recommendations.
  461. Our regions evaluate the program. Contraception by injectable progestin, Depo Provera: opportunity, continuity and analyses of the situation in central west Tunisia. [Nos regions evaluent le programme. La contraception par progestatif injectable, Depo-Provera: opportunite, continuite et analyses de la situation au Centre-Ouest (Tunisie)]
  462. Outercourse as a safe and sensible alternative to contraceptives [letter]
  463. An overview on the effectiveness of natural family planning.
  464. Overview: family planning in India.
  465. Pakistan and Bangladesh: matching Islamic values with sexual and family planning.
  466. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus.
  467. Pattern of contraceptive use by residents of a village in South Delhi.
  468. Patterns of fertility and contraceptive use in Tanzania [abstract]
  469. The pediatrician and the sexually active adolescent. Sexual activity and contraception.
  470. Perceptions of contraceptive effectiveness and health effects of oral contraception.
  471. Perceptions of family planning and reproductive health issues: focus group discussions in Kazakhstan, Turkmenistan, Kyrgyzstan, and Uzbekistan.
  472. Perceptions of oral contraceptives: pretest results of a new package label.
  473. Perspectives on commercial sector involvement in family planning services. A summary.
  474. Perspectives on the local manufacture of contraceptives. A summary.
  475. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.
  476. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy.
  477. Phase II clinical trial of a vas deferens injectable contraceptive for the male.
  478. Phaseout of donated contraceptives: lessons learned from the case of CEPEO.
  479. The pill and other forms of hormonal contraception. 5th ed.
  480. Pills backed as emergency contraception.
  481. Planning and implementation of the appraisal of family planning services' quality of care.
  482. Planning skills in adolescence: the case of contraceptive use and non-use.
  483. The politics of reproductive benefits: U.S. insurance coverage of contraceptive and infertility treatments.
  484. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
  485. The possible use of antiprogestins for contraception.
  486. Post-abortion family planning: a practical guide for programme managers.
  487. Postcoital contraception. An emergency option. [Contraception postcoital. Una opcion de emergencia.]
  488. Postcoital contraception. Data from five years of use in an outpatient clinic. [Intercezione post-coitale. Dati relativi a cinque anni di utilizzo in un consultorio privato.]
  489. Postnatal contraceptive advice -- midwives' attitudes.
  490. Postpartum and postabortion family planning in Latin America: interviews with health providers, policy-makers and women's advocates in Ecuador, Honduras and Mexico.
  491. Postpartum contraception using the POP [letter]
  492. Postpartum contraception. [Contracepcao pos-parto.]
  493. Postpartum contraception: the lactational amenorrhea method.
  494. Practical pointers for conducting commercial sector family planning regulatory assessments.
  495. Predicting contraceptive vigilance in adolescent females: a projective method for assessing ego development.
  496. Pregnancy complications in natural family planning users.
  497. Pregnancy outcome in natural family planning users: cohort and case-control studies evaluating safety.
  498. Premature introduction of progestin-only contraceptive methods during lactation.
  499. Prescribing long-acting progestin-only contraceptives for adolescents.
  500. Prescription drug products; certain combined oral contraceptives for use as postcoital emergency contraception. Notice of the Food and Drug Administration. Dated 20 February 1997.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.